Trials / Completed
CompletedNCT01469130
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will investigate the safety and tolerability and determine the MTD of MEK162 in Japanese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEK162 | MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets). |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-04-01
- Completion
- 2018-02-01
- First posted
- 2011-11-10
- Last updated
- 2020-10-05
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01469130. Inclusion in this directory is not an endorsement.